Cargando…
PB2146: CHARACTERISTICS AND OUTCOMES OF COVID-19 IN PATIENTS WITH PLASMA CELL DISORDERS DURING THE FIRST OMICRON WAVE IN BEIJING SINCE DECEMBER 2022: A RETROSPECTIVE STUDY AT A TERTIARY CENTER
Autores principales: | He, Qing, Dou, Xuelin, Liu, Yang, Peng, Nan, Gong, Lizong, Wen, Lei, Lu, Jin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429412/ http://dx.doi.org/10.1097/01.HS9.0000975344.69152.0f |
Ejemplares similares
-
PB2146: A PHASE 2, OPEN-LABEL STUDY OF LONCASTUXIMAB TESIRINE IN COMBINATION WITH RITUXIMAB (LONCA-R) IN PREVIOUSLY UNTREATED UNFIT/FRAIL PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (LOTIS-9)
por: Westin, J., et al.
Publicado: (2022) -
PB2065: SEVERE HEMOLYSIS OF PNH PATIENTS ASSOCIATED WITH OMICRON INFECTION IN CHINA
por: Yang, Hui, et al.
Publicado: (2023) -
PB2161: BORTEZOMIB, POMALIDOMIDE, AND DEXAMETHASONE IS AN EFFECTIVE REGIMEN FOR PATIENTS WITH RELAPSE AND REFRACTORY AL AMYLOIDOSIS AND MONOCLONAL IMMUNOGLOBULIN DEPOSITION DISEASE
por: Liu, Yang, et al.
Publicado: (2023) -
PB1969: PATIENTS WITH CHRONIC MYELOID LEUKEMIA AND CORONAVIRUS DISEASE 2019 IN THE OMICRON ERA
por: Qi, Feiyang, et al.
Publicado: (2023) -
PB2578: ANTIBODY RESPONSE TO SARS-COV-2 OMICRON VARIANT IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES AFTER THE BREAKTHROUGH INFECTION WAVE IN CHONGQING, CHINA: A MULTI-CENTER, PROSPECTIVE STUDY
por: Jun, LI, et al.
Publicado: (2023)